| ￥2500 | |
| Z05372-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||||
| Protein Construction |
|
||||||
| Purity |
> 95% as determined by BisTris PAGE > 95% as determined by HPLC |
||||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||||
| Biological Activity | Measured by its binding ability in a functional ELISA. Immobilized Her4/ErbB4, His & Avi, Human at 2μg/ml (100μl/well) on the plate can bind Human NRG1 Beta 1, hFc Tag. Test result was comparable to standard batch. | ||||||
| Expression System | HEK293 | ||||||
| Theoretical Molecular Weight | 72.7 kDa | ||||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 80-110 kDa based on Bis-Tris PAGE result. | ||||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||||
| Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background | Her4, a member of the EGF receptor family, plays a variety of roles in physiological and pathological states. Genetic studies have indicated a link between Her4 and type 2 diabetes and obesity. Her4 may play an important role in glucose homeostasis and lipogenesis. Her4 deficiency-related obesity and adipose tissue inflammation may contribute to the development of MetS. |
| Synonyms | p180erbB4; 4ICD; E4ICD; HER4; ErbB4; MGC138404; ALS19 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
